HPV Vaccination

The quadrivalent HPV vaccine also covers HPV 6 and 11, which cause warts. The nonavalent HPV vaccine protects against five additional cancer-causing HPV types beyond HPV 16 and 18. HPV vaccine immunity has persisted for more than a decade after vaccination. Cervarix and Gardasil protect against more than 95% of infections caused by HPV types 16 and 18. The HPV vaccine is presented as an effective preventive measure against HPV infection. Among AYAs eligible for HPV catch-up vaccination, cancer survivors were significantly more likely to initiate vaccination (28.1% vs 18.5%) and to complete it by end of follow-up (20.6% vs 5.4%). Cancer survivors were more likely to have completed the initial HPV vaccination schedule before the study's catch-up period began (15.9% vs 11.7%). The WHO recommends vaccinating girls aged 9 to 14 with one or two doses before sexual debut when possible. The CDC recommends three HPV vaccine doses for individuals aged 18-26. Current WHO recommendations include single-dose HPV vaccine schedules in certain age groups. National HPV vaccine coverage fell sharply from 32% of girls completing the series in 2018 to only 18% by 2022, far below the PAHO and WHO 90%…